Altogether, these findings indicate that ITCs are efficient agents blocking the formation of mutant huntingtin aggregates, which are the main cause of its toxicity, and thus might have a potential in developing therapeutics for Huntington’s disease and, perhaps, other proteinopathies. This evidence concerns the gene HTT and juvenile Huntington disease.